Results 201 to 210 of about 191,709 (318)

Peritoneal Dialysis‐Related Mycobacterium fortuitum Exit‐Site/Tunnel Infection in a Pediatric Patient: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT In patients in peritoneal dialysis (PD) who develop exit site and/or catheter tunnel infections, expeditious identification of the causative organism and early implementation of treatment are important to ensure good outcomes. Among the many causative organisms, the diagnosis of Mycobacterium fortuitum is particularly challenging, with its ...
Rina Takahashi, Hiroshi Tamura, Keishiro Furuie, Hiroko Nagata, Shohei Kuraoka   +4 more
wiley   +1 more source

The Quantification of Drug Accumulation within Gram-Negative Bacteria. [PDF]

ACS Infect Dis
George A, Shivangi, Bozan A, Spencer K, Terlecky AJ, Ahn YM, Barnett PR, Kreiswirth BN, Freundlich JS.   +8 more
europepmc   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis. [PDF]

Clin Infect Dis
de Jager V, Mockeliunas L, You H, Simonsson USH, Collings T, Upton CM, Bezuidenhout JA, Gupte N, Dorman SE, Nuermberger E, Lamichhane G, Diacon AH, Dooley KE.   +12 more
europepmc   +1 more source

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 314-317, February 2026.
Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug–drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI‐related parameters have often been considered a limitation for predicting PBPK‐DDIs.
Kunal S. Taskar, Pradeep Sharma, Karen Rowland Yeo   +2 more
wiley   +1 more source

Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying 'breakpoints in brackets'. [PDF]

J Antimicrob Chemother
Boyd SE, Wootton M, Howe RA, Livermore DM, Macgowan AP, Kahlmeter G.   +5 more
europepmc   +1 more source

Coevolution and Functional Effects of Endosymbiotic Rickettsia in Leptocybe invasa Fisher & LaSalle (Hymenoptera: Eulophidae) Across China

Ecology and Evolution, Volume 16, Issue 2, February 2026.
Two distinct lineages of L. invasa and the dominant endosymbiont, Rickettsia, was identified, followed by an analysis of its infection density across various developmental stages and tissues of L. invasa. Furthermore, two distinct strains of the Rickettsia endosymbiont were detected, and the phylogenetic relationships between these strains and their L.
Xiu Xu, Leming Zhou, Jinting Xie, Junjue Li, Chunhui Guo, Zhende Yang   +5 more
wiley   +1 more source

Tuberculosis prevention in children, adolescents, and pregnant and postpartum women in South Africa. [PDF]

S Afr Fam Pract (2004)
Rabe M, Hughes JA.
europepmc   +1 more source

Deconvoluting Gut Versus Liver Cytochrome P450 3A4 Function: Drug Probes, Biomarkers, and Tissue Biopsy

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Cytochrome P450 3A4 (CYP3A4) is an important drug‐metabolizing enzyme, whose function is impacted by age, sex, body weight, pregnancy, and disease. It is also the site of major drug interactions involving inhibition and induction. Because CYP3A4 is expressed in the intestine and liver, investigators have sought to study its function in both ...
David Rodrigues
wiley   +1 more source